<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2014011416223N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-01-23</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of diet therapy as epigenetic factors in the control of diabetic complications</public_title>
      <acronym></acronym>
      <scientific_title>The effect of low calorie diet on plasma levels of miR-33b, -375, -935 and -29a, state of insulin ‎resistance and lipid metabolism in obese women with type II diabetes ‎</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2014-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/15251</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Type 2 diabetes mellitus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A 8-week low calorie diet ‎‏)‏based on subtracting 700 calories from standard formula to ‎predict energy expenditure estimated at four levels of physical activity for obese women 19 years old and ‎above‏(‏‎ and planning individual diet based on exchange list.‎. Intervention 2: Control group: without low calorie diet- Continuing with their common diet for 8-week.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Somayeh Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nutrition department, Faculty of nutrition sciences, Attar neyshabouri street, Golgasht avenue</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 41133575803</telephone>
        <email>mohammadis.phd@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Somayeh Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Public nutrition department, Faculty og nutrition sciences, Attar neyshabouri Avenue, Golgasht street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 41133575803</telephone>
        <email>Mohammadis.phd@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The inclusion criteria: Women with type 2 diabetes diagnosed at least two years by specialist; The ‎age range of 25 to 60; The degree of obesity in accordance with the definition of a BMI ≤ 45 ‎kg/m2 ≥ 30;  Willingness to participate in research.‎&#13;
The exclusion criteria: Patients who did not complete the questionnaire; Unwillingness to blood ‎sampling; BMI over 45; Following a special diet like vegetarian diet, low calorie diet or weight-‎loss medications for obesity last year; More than three kilograms of weight change over the past ‎six months; Pregnancy, lactation, menstruation irregular; Chronic cigarette smokers (3 days more ‎than 48 months) or alcohol; Vitamin and mineral supplements; protein and phytoestrogens period ‎of 3 months prior to study entry; Taking hormonal contraceptives, anticonvulsants, ‎glucocorticoids during the recent 3 months;  Patients with type 1 diabetes mellitus; Kidney ‎disease, liver disease, hyperthyroidism, a chronic inflammation (such as rheumatoid arthritis, ‎multiple sclerosis, rash, etc.) and a variety of benign and malignant masses.‎</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Non-insulin-dependent diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A 8-week low calorie diet ‎‏)‏based on subtracting 700 calories from standard formula to ‎predict energy expenditure estimated at four levels of physical activity for obese women 19 years old and ‎above‏(‏‎ and planning individual diet based on exchange list.‎</i_keyword>
      <i_keyword>Control group: without low calorie diet- Continuing with their common diet for 8-week</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Micro RNA-29a. Timepoint: before and 2 month after  intervention. Method of measurement: qRT-PCR, copy nomber of micro RNAs per each micro litr of plasma and deffrent percent with interior standard.</prim_outcome>
      <prim_outcome>Micro rna-375. Timepoint: before and 2 month after  intervention. Method of measurement: qRT-PCR, copy nomber of micro RNAs per each micro litr of plasma and deffrent percent with interior standard.</prim_outcome>
      <prim_outcome>Micro RNA-33b. Timepoint: before and 2 month after  intervention. Method of measurement: qRT-PCR, copy nomber of micro RNAs per each micro litr of plasma and deffrent percent with interior standard.</prim_outcome>
      <prim_outcome>Micro RNA-935. Timepoint: before and 2 month after  intervention. Method of measurement: qRT-PCR, copy nomber of micro RNAs/ micro litr of plasma and deffrent percent with interior standard.</prim_outcome>
      <prim_outcome>Fasting serum insulin concentration. Timepoint: before and 2 month after  intervention. Method of measurement: ELISA, ‎µU/mL.</prim_outcome>
      <prim_outcome>Plasma insulin concentration 2 hours after meal. Timepoint: before and 2 month after  intervention. Method of measurement: ELISA, ‎µU/mL.</prim_outcome>
      <prim_outcome>Serum adiponectin levels. Timepoint: before and 2 month after  intervention. Method of measurement: ELISA, ng/dL.</prim_outcome>
      <prim_outcome>Serum TNF-a levels. Timepoint: before and 2 month after  intervention. Method of measurement: ELISA, ng/dL.</prim_outcome>
      <prim_outcome>Fasting blood glucose. Timepoint: before and 2 month after  intervention. Method of measurement: enzymatic colorimetric assay, mg/dL.</prim_outcome>
      <prim_outcome>Blood glucose, blood glucose 2 hours after meal. Timepoint: before and 2 month after  intervention. Method of measurement: enzymatic colorimetric assay, mg/dL.</prim_outcome>
      <prim_outcome>Serum total cholestrol. Timepoint: before and 2 month after  intervention. Method of measurement: enzymatic colorimetric assay, mg/dL.</prim_outcome>
      <prim_outcome>Serum LDL-C. Timepoint: before and 2 month after  intervention. Method of measurement: enzymatic colorimetric assay, mg/dL.</prim_outcome>
      <prim_outcome>Serum HDL-C. Timepoint: before and 2 month after  intervention. Method of measurement: enzymatic colorimetric assay, mg/dL.</prim_outcome>
      <prim_outcome>Serum triglyceride level. Timepoint: before and 2 month after  intervention. Method of measurement: enzymatic colorimetric assay, mg/dL.</prim_outcome>
      <prim_outcome>Weight. Timepoint: before, 1 and 2 month after  intervention. Method of measurement: Scale of body analyzer, Kg.</prim_outcome>
      <prim_outcome>BMI. Timepoint: before, 1 and 2 month after  intervention. Method of measurement: Calculating by equation, Kg/m2‎.</prim_outcome>
      <prim_outcome>Waist circumference. Timepoint: before, 1 and 2 month after  intervention. Method of measurement: Tape, Centimeter.</prim_outcome>
      <prim_outcome>Hip circumference. Timepoint: before, 1 and 2 month after  intervention. Method of measurement: Tape, Centimeter.</prim_outcome>
      <prim_outcome>Waist to hip ratio. Timepoint: before, 1 and 2 month after  intervention. Method of measurement: Calculating by equation, cm/cm.</prim_outcome>
      <prim_outcome>Waist to height ratio. Timepoint: before, 1 and 2 month after  intervention. Method of measurement: Calculating by equation, m/m.</prim_outcome>
      <prim_outcome>HOMA-IR. Timepoint: before and 2 month after  intervention. Method of measurement: HOMA-IR equation.</prim_outcome>
      <prim_outcome>QUICKI. Timepoint: before, 1 and 2 month after  intervention. Method of measurement: QUICKI equation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Calorie intake. Timepoint: Before, 1 month and 2 month after intervention. Method of measurement: 3 day food recall and Food frequency questionnaire, Kcal/day.</sec_outcome>
      <sec_outcome>Carbohdrate inake. Timepoint: Before, 1 month and 2 month after intervention. Method of measurement: 3 day food recall and Food frequency questionnaire, g/day.</sec_outcome>
      <sec_outcome>Protein intake. Timepoint: Before, 1 month and 2 month after intervention. Method of measurement: 3 day food recall and Food frequency questionnaire, g/day.</sec_outcome>
      <sec_outcome>Fat intake. Timepoint: Before, 1 month and 2 month after intervention. Method of measurement: 3 day food recall and Food frequency questionnaire,g/day.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Shahid Beheshti University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-12-16</approval_date>
        <contact_name>Tabriz University of Medical Sciences</contact_name>
        <contact_address>Tabriz University of Medical Sciences, Research vice-chancellors, Golgasht st, Azadi ave, Tabriz, Iran Tabriz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
